Concepedia

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study

Peter Vuylsteke, Manon Huizing, Katarína Petráková, Rebecca Roylance, Robert Laing, Stephen Chan, F. Abell, Steven Gendreau, Isabelle Rooney, Doris Apt,

Annals of Oncology · 2016 · 114 citations · 11 references

DOIFull text

Open access

Concepts

References

11

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Arkaitz Carracedo, Li Ma, Julie Teruya‐Feldstein et al. · Journal of Clinical Investigation · 2008 · 1.4K citations · Full text

, , +17

The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Adrian Folkes, Khatereh Ahmadi, W. Alderton et al. · Journal of Medicinal Chemistry · 2008 · 746 citations · Full text

, , +13

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Fátima Cardoso, A. Costa, Larry Norton et al. · Annals of Oncology · 2014 · 539 citations · Full text

, , +15

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Debashis Sarker, Joo Ern Ang, Richard D. Baird et al. · Clinical Cancer Research · 2014 · 360 citations · Full text

, , +15

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Fátima Cardoso, A. Costa, Larry Norton et al. · The Breast · 2014 · 335 citations · Full text

, , +15